이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중장 신경내분비 종양에서 PRRT 후 소마토스타틴 유사체 중단 (STOPNET)

2026년 11월 9일 업데이트: Australasian Gastro-Intestinal Trials Group

중장 신경내분비 종양에서 펩티드 수용체 방사성 핵종 치료 후 소마토스타틴 유사체 중단에 대한 무작위 연구(STOPNET)

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.

The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.

STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.

The two primary objectives include

  1. To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.

  2. Feasibility as measured by:

    1. Recruitment rate and
    2. Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.

The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.

연구 유형

중재적

등록 (추정된)

78

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Alberta
      • Edmonton, Alberta, 캐나다, T6G 1Z2
        • 모병
        • Cross Cancer Institute
        • 연락하다:
        • 수석 연구원:
          • Dr Stella Koumna
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 4E6
    • Ontario
      • London, Ontario, 캐나다, N6A 5W9
        • 모병
        • London Health Sciences Centre Research Institute (LHSCRI)
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Dr David Laidley
      • Ottawa, Ontario, 캐나다, K1Y 1J8
        • 모병
        • Ottawa Hospital Research Institute
        • 연락하다:
        • 수석 연구원:
          • Dr Rachel Goodwin
      • Toronto, Ontario, 캐나다, M5G 2M9
        • 모병
        • University Health Network Princess Margaret Cancer Centre
        • 연락하다:
        • 수석 연구원:
          • Dr Raymond Jang
      • Toronto, Ontario, 캐나다, TG 260
        • 모병
        • Odette Cancer Centre Sunnybrook Health Sciences Centre
        • 연락하다:
        • 수석 연구원:
          • Dr Sten Myrehaug
    • Saskatchewan
      • Regina, Saskatchewan, 캐나다, S4T 7T1
        • 모병
        • Allan Blair Cancer Centre
        • 연락하다:
        • 수석 연구원:
          • Dr Mussawar Iqbal
      • Saskatoon, Saskatchewan, 캐나다, S7N 4H
        • 모병
        • Saskatoon Cancer Centre
        • 연락하다:
        • 수석 연구원:
          • Dr Mita Manna
    • New South Wales
      • Sydney, New South Wales, 호주, 2065
      • Wollongong, New South Wales, 호주, 2502
    • Queensland
      • Brisbane, Queensland, 호주, 4006
      • Cairns, Queensland, 호주, 4870
      • Toowoomba, Queensland, 호주, 4350
    • South Australia
      • Adelaide, South Australia, 호주, 5000
        • 모병
        • The Queen Elizabeth Hospital
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Prof Timothy Price
    • Victoria
      • Melbourne, Victoria, 호주, 3000
        • 모병
        • Peter MacCallum Cancer Centre
        • 연락하다:
        • 수석 연구원:
          • Dr Hui-Li Wong
        • 연락하다:
    • Western Australia
      • Kalgoorlie-Boulder, Western Australia, 호주, 6430
      • Perth, Western Australia, 호주, 6150

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).

  2. Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.

  3. Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).

    • Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.

  4. Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.

    In addition, for this study, non-functioning tumour is defined as:

    • Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.

    • Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.

    • For mid and hind gut (GI cohort) patients:

      • 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) <3x upper limit of normal.
      • No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
    • Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.

  5. Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.

  6. Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.

  7. PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).

  8. ECOG performance status 0-2.

  9. Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.

  10. Adequate renal, hepatic and haematologic function as judged by the treating team.

  11. Life expectancy of at least 12 months.

Exclusion Criteria:

  1. This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
  2. Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
  3. Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
  4. Any contraindication to PRRT, as per local institutional practice.
  5. Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.
  6. Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
  7. Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off corticosteroids for at least 2 weeks.
  8. Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
  9. Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
  10. Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Continue SSA

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

다른 이름들:
  • SSA 계속
실험적: Cease SSA

Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time.

Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.

다른 이름들:
  • SSA 중단

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
20-month progression free survival rate after PRRT
기간: 20 months

Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA.

20 months
Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
기간: 20 months
  1. Proportion of participants that remained on the SSA cessation arm for the duration of the 20-month study follow up (patient acceptance of SSA cessation).
  2. Rate of recruitment: ability to complete recruitment over the 24-month recruitment period
20 months

2차 결과 측정

결과 측정
측정값 설명
기간
Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales
기간: 20 months

Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning.

20 months
Measure Quality of life using the EORTC QLQ-GINET21 scales
기간: 20 months

Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms.

20 months
Cost-effectiveness of SSA therapy cessation
기간: The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.

Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively.

The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
Psycho-oncological impacts of SSA therapy cessation: Decision Regret
기간: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree)

20 months
Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression
기간: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often)

20 months
Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict
기간: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree)

20 months
Time to commencement of subsequent therapy
기간: 20 months

Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies)

20 months
Overall survival
기간: 20 months

Estimate the 20-month overall survival rate in patients who cease and who continue SSA.

20 months
Rates of SSA being recommenced over time
기간: 20 months

Cumulative percentage of SSA recommencement over time.

20 months

기타 결과 측정

결과 측정
측정값 설명
기간
Exploratory analyses
기간: 20 months

Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA.

20 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 10월 14일

기본 완료 (추정된)

2027년 9월 1일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2024년 3월 14일

QC 기준을 충족하는 최초 제출

2024년 4월 1일

처음 게시됨 (실제)

2024년 4월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • AG0219NET

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .